Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZNCF) Current Deferred Revenue (2018 - 2020)

Historic Current Deferred Revenue for Astrazeneca (AZNCF) over the last 3 years, with Q4 2020 value amounting to $12.0 million.

  • Astrazeneca's Current Deferred Revenue fell 5714.29% to $12.0 million in Q4 2020 from the same period last year, while for Dec 2020 it was $12.0 million, marking a year-over-year decrease of 5714.29%. This contributed to the annual value of $12.0 million for FY2020, which is 5714.29% down from last year.
  • Astrazeneca's Current Deferred Revenue amounted to $12.0 million in Q4 2020, which was down 5714.29% from $28.0 million recorded in Q4 2019.
  • Over the past 5 years, Astrazeneca's Current Deferred Revenue peaked at $92.0 million during Q4 2018, and registered a low of $12.0 million during Q4 2020.
  • For the 3-year period, Astrazeneca's Current Deferred Revenue averaged around $44.0 million, with its median value being $28.0 million (2019).
  • Per our database at Business Quant, Astrazeneca's Current Deferred Revenue plummeted by 6956.52% in 2019 and then plummeted by 5714.29% in 2020.
  • Quarter analysis of 3 years shows Astrazeneca's Current Deferred Revenue stood at $92.0 million in 2018, then tumbled by 69.57% to $28.0 million in 2019, then plummeted by 57.14% to $12.0 million in 2020.
  • Its Current Deferred Revenue was $12.0 million in Q4 2020, compared to $28.0 million in Q4 2019 and $92.0 million in Q4 2018.